Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
|Articles|May 30, 2019
Speaking with David Van Sickle, CEO, Propeller Health
David Van Sickle, CEO, Propeller Health, talks with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event about how the digital therapeutics landscape has changed.
Advertisement
David Van Sickle, CEO, Propeller Health, talks with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event about how the digital therapeutics landscape has changed.
Advertisement
Related to this article
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
4
MFN Is an Offer Pharma Can’t Refuse
5